|
Hier mal eine meiner Meinung nach sehr gelungene Zusammenfassung aus einem amerikanischen Board über die Aktivitäten von DNAP (abgeschlossen - in Arbeit - geplant): DNAP Research and Product Development – Milestones For Forensics and Consumer Markets ANCESTRYbyDNA 2.0(TM) R/D 2000-01… 4Q 2002 market… Mar2004*replaced w/ V2.5 ANCESTRYbyDNA 2.5(TM) R/D 2003………….Feb2004 market ANCESTRYbyDNA 3.0(TM) R/D 2005………2006 market? EURO-DNA(TM) 1.0 R/D 2003……….......4Q 2004 market DNAWitness(TM) 2.0 R/D 2002…………….2003 market……...2004*replaced w/ V2.5 DNAWitness(TM) 2.5 …R/D 2003...July 2004 market…Test kit - late 2005 ...global sales 2006 DNAWitness(TM) 3.0………………………………...............R/D 2005 (3.0 to include eye color) EURO Witness(TM) 1.0………………………………R/D 2004………….Feb2005 market RETINOME(TM) 1.0 Eyecolor. …R/D 2003....4Q 2004 market…Test kit - late 2005…global sales 2006 RETINOME HA[(TM) Haircolor…….R/D 2004….2005-06 validate…..2007 beta test……..2008 market? SKIN SHADE………………………………….R/D 2005…………...R/D 2006-07……2008 market? Genetic Family Tree DB………….………………………………R/D 2004………….online 2005 Searchable Ancestry Genealogy DB…………...R/D 2003…….online 2004……….expand 2005 Searchable PhotoAncestryDB (Forensics)……R/D 2003……..online 2004………..expand 2005 DNA Database for Native Americans…develop 2003/2004….expand 2005 DNA Database for African-Americans….develop 2005 DNAP Research and Product Development – Milestones For Pharmacogenomics and Theranostics DNAP– Drug Research Projects: 1) Ovanome - Taxol/Carboplatin efficacy * R/D 1998.…Announce Mar 2000…Validation Studies 2002-2004….Clinical Study May 2005…FDA IND late 2006…. 2) Statinome - Lipitor, Zocor, efficacy, liver, muscle adverse myalgia response * R/D 1998….Clinical Studies late 2004/early 2005…FDA IND 2007?...Market?... 3) Acenome - Enalapril, Lisinopril efficacy, muscle, adverse cough * R/D 1998….Clinical Studies late 2004/early 2005…FDA IND 2007?...Market?... 4) Immunosuppressants - Sirolimus, Tacrolimus, Mycophenolate * R/D 2001…NYU Open R/D?…. 5) Super EPO Anemia Drug * License Apr 2005…Pre-clinical 4thQ 2005/2006…FDA IND late 2006/early 2007…. * DNAP exclusive worldwide license to develop a Super EPO drug with a $10 billion dollar market potential. 6) Acute Lymphocyte Leukemia (ALL) * R/D 2005…Joint Publication late 2005….DNA Screening Test 2006?….. 7) Cervical Cancer and ETS * FAMRI Grant Feb 2003….2 year grant….Publication 2006?.... DNAP and Moffitt Cancer Center – Drug Research Projects: Cancer research partnership announced March 2004…R/D ongoing for over one year… 1) Response of Metastatic Colorectal Cancer to Irinotecan/Capecitabine (Xeliri) and Oxaliplatin/Capecitabine (Xelox) 2) Melphalan and Topotecan (MT) efficacy for treatment of Multiple Myeloma 3) Cyclophosphamide efficacy 4) Organistron adverse events - post operative nausea and vomiting 5) Esophageal malignancy chemotherapy response - standard FDA treatment Note: All above data on DNAP`s research and drug product pipeline are from DNAP newsletters, PR`s and SEC filings. Projects listed may or may not be inclusive of all possible projects DNAP may be involved in. Please feel free to add or update. * JMHO – The above numerous unique forensics and consumer products and cancer research projects, and especially our new Super EPO anemia drug, are more “tools” by far than most all other biotech’s have put together. Not listed above are DNAP’s pending patents, journal articles, publications, actively working with many US law enforcement agencies, the FBI, New Scotland Yard, Australia and others. They have successfully helped in numerous cases and are currently involved with at least 80 others, getting DNA Witness test kits ready for mass production and global sales for the forensics markets. And the most exciting recent MAJOR accomplishment by DNAP’s management team is that they put DNAPrint Genomics solidly on the drug development path with our own drug. This management team has recently licensed a Super EPO anemia drug with a $10 billion dollar market potential with Harvard’s affiliate, Beth Israel, and turned DNAPrint Genomics into a new small drug company….this accomplishment alone is brilliant and worth investors support for management. It definitely has mine… DNAP has a heck of a lot more going for it than the normal small company doing an R/S to survive. Management has accomplished much in under 2 years and has earned my continued support to take us the next step....DNAP as a successful small drug company. It will be a combination of many of the above and/or some new blockbuster stuff going on behind the scenes that will keep us on track after any R/S... Of course...do your own DD and make your own decisions...but for a lowly penny, I`m in for the ride and I`m betting on the potential. God’s Speed To DNAP and To All DNAP Investors, Robert |
|
| aus der Diskussion: | DNAPrint Genomics ...... wann, wenn nicht 2004! |
| Autor (Datum des Eintrages): | Michiko (28.05.05 12:47:44) |
| Beitrag: | 549 von 657 (ID:16735601) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |